Genpact Supports embecta's Spin-Off into an Independent Diabetes Care Company

Core Insights - Genpact is collaborating with embecta to support its transition from Becton Dickinson and Company, focusing on enhancing operations in the diabetes technology market [1][2] - The partnership aims to leverage Genpact's expertise in data, technology, and AI to improve healthcare outcomes for diabetes patients [2] Group 1: Partnership and Operations - Genpact has played a crucial role in embecta's spin-off from BD, modernizing its operations through the implementation of a robust ERP system and standardized global processes [2] - The collaboration has established end-to-end HR, finance, and procurement processes, ensuring uninterrupted customer support and supply chain stability for embecta [2][3] - This partnership enables embecta to provide insulin injection devices to 30 million people across more than 100 countries without interruption [2] Group 2: Leadership Perspectives - The relationship between Genpact and embecta is founded on shared values and a commitment to mutual success, facilitating a smooth transition to an independent entity [3] - Both companies are dedicated to improving the lives of people living with diabetes, aligning their missions for better healthcare solutions [2][3] Group 3: Company Overview - Genpact is a global professional services firm with over 125,000 employees across more than 30 countries, focusing on creating lasting value for clients [4] - The company emphasizes its purpose of pursuing a world that works better for people, serving leading enterprises including Fortune Global 500 companies [4]